Merck is introducing its muscle mass to the battle in opposition to COVID-19, asserting moves to build a vaccine with an Austrian biotech company and a study nonprofit.
The world’s premier vaccine maker said Monday it will get Vienna-based Themis, which has been performing with the Institut Pasteur on a COVID-19 vaccine based on a measles vaccine.
“We are keen to mix our strengths the two to build an powerful COVID-19 vaccine in the in close proximity to phrase and to construct a pandemic preparedness ability directed toward emerging agents that pose a long term epidemic danger,” Dr. Roger Perlmutter, president of Merck Exploration Laboratories, said in a information release.
In a further significant shift, Merck is partnering with the nonprofit IAVI on the enhancement of a vaccine linked to Merck’s existing Ebola vaccine.
As FierceBiotech stories, Merck, whose vaccine business enterprise produced gross sales of $eight.4 billion past 12